Yhn HealthHealth first seen 9 d ago, last 2 d ago, peak #1
Moderna and Merck say mRNA cancer vaccine cut death, recurrence by 42%
Original: Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck report that their personalized mRNA cancer vaccine, developed for melanoma, reduced risk of death and cancer recurrence by 42% in trial results published in October 2026. The findings mark a significant step for mRNA technology beyond COVID vaccines, and observers are weighing what the results mean for the future of personalized cancer treatment and the companies' next regulatory steps.
Why now: New clinical trial data shows a major survival benefit from an mRNA-based personalized cancer therapy, drawing wide attention to advances in cancer treatment.
Evidence
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% · _Microft · 212
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% · nathcd · 6
API: https://socialmediatrends-api.osmike.com/v1/trends/3528419